New imaging technology for identifying breast cancer and lymph node status
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
This study is testing a new imaging technology to help doctors better identify breast cancer and check lymph nodes during surgery for patients with breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Yunnan Cancer Hospital Academic / other |
| Locations | 1 site (Kunming, Yunnan) |
| Trial ID | NCT06713161 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the use of near-infrared-II (NIR-II) fluorescent molecular probes to accurately identify breast cancer tissue and assess sentinel lymph node (SLN) metastatic status during surgery. Patients undergoing surgical treatment for breast cancer will have their excised tissues incubated with a specific probe, followed by imaging to differentiate between cancerous and normal tissues. The accuracy of the imaging results will be confirmed through pathological examination, aiming to improve surgical outcomes and reduce the need for additional operations.
Who should consider this trial
Good fit: Ideal candidates for this study are adult females aged 18-75 with a resectable breast nodule or mass.
Not a fit: Patients with serious cardiopulmonary disease or other contraindications to surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this technology could lead to more precise surgical interventions and better outcomes for breast cancer patients.
How similar studies have performed: While the use of NIR-II fluorescence imaging is promising, this specific approach is novel and has not been extensively tested in clinical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients between 18-75 years of age * Female * Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment * Good operative candidate * Subject capable of giving informed consent and participating in the process of consent Exclusion Criteria: * Patients unable to participate in the consent process * Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc * Other conditions that the researcher considers inappropriate to participate in the study
Where this trial is running
Kunming, Yunnan
- Yunnan Cancer Hospital — Kunming, Yunnan, China (Recruiting)
Study contacts
- Study coordinator: Yuanyuan Zhu,Doctor
- Email: 18059766094@163.com
- Phone: 86+18059766094
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.